Home›Stock Screener›GlaxoSmithKline Pharmaceuticals›Quarterly Results

GlaxoSmithKline Pharmaceuticals Quarterly Results for Trading Insights

Latest Quarter Net Profit
₹278 Cr
QMar 2026
Quarterly Results

In Mar 2026, GlaxoSmithKline Pharmaceuticals (GLAXO) reported revenue ₹1,031 Cr and net profit ₹278 Cr — revenue +1.6% YoY. For annual financials, live price and key ratios, visit GlaxoSmithKline Pharmaceutical share price chart.

GLAXO Quarterly Results — Revenue, Profit & EPS Highlights

GlaxoSmithKline Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with GLAXO DCF valuation to assess whether the stock is under or overvalued.

  • Revenue of ₹1,031 Cr in Mar 2026 (+1.5% vs Sept 2025, +1.6% vs Mar 2025)
  • Net Profit of ₹278 Cr in Mar 2026 (+7.8% vs Sept 2025, +5.7% vs Mar 2025)
  • EBITDA of ₹387 Cr in Mar 2026 (+4.0% vs Sept 2025)
  • Operating Margin of 35.0% in Mar 2026 (+1.0pp vs Sept 2025)
  • Earnings Per Share of ₹16.40 in Mar 2026 (+8.8% vs Sept 2025)

GlaxoSmithKline Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS

GLAXO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 QoQ YoY
Revenue (₹ Cr) 1,031 1,016 1,015 849 1,091 1.5% 1.6%
Net Profit (₹ Cr) 278 258 263 205 296 - -
EBITDA (₹ Cr) 387 372 374 295 421 - -
EPS (₹) 16.40 15.07 15.52 12.10 16.54 - -
Operating Margin (%) 35.0% 34.0% 34.0% 31.0% 36.0% - -

GLAXO Share Price Trend — 1-Year Movement Across Quarterly Results

GlaxoSmithKline Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore GLAXO share price charts to track price trends across different timeframes.

Profitability Ratios

Profit Margin 27.0%
EBITDA Margin 37.5%
Operating Margin 35.0%
ROE (Annual) 49.1%

Balance Sheet Highlights

Total Assets ₹4,324 Cr
Total Equity ₹2,267 Cr
Current Assets ₹3,606 Cr
Current Liabilities ₹277 Cr

Cash Flow Analysis

Operating Cash Flow ₹1,290 Cr
Investing Cash Flow ₹-46 Cr
Financing Cash Flow ₹-769 Cr
Net Cash Flow ₹475 Cr

Current Market Data

Current Price ₹2296.20
Exchange NSE
Last Updated May 27, 2026

Revenue Trend (₹ Cr)

Jun 2025 849
Mar 2025 1,015
Sept 2025 1,016
Mar 2026 1,031

Net Profit Trend (₹ Cr)

Jun 2025 205
Mar 2025 263
Sept 2025 258
Mar 2026 278

Operating Margin Trend (%)

Jun 2025 31.0%
Mar 2025 34.0%
Sept 2025 34.0%
Mar 2026 35.0%

GLAXO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

GlaxoSmithKline Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹442,581.33 Cr 1844.3 15,018 2,710 +1.0% +11.8% 18.0% 163.2
Divis Laboratories
Mar 2026 		₹179,363.85 Cr 6797.5 2,986 751 +4.4% +11.8% 25.2% 240.1
Torrent Pharmaceuti…
Mar 2026 		₹153,579.77 Cr 4537.8 4,111 364 +27.7% +42.2% 8.9% 394.2
Cipla
Mar 2026 		₹114,559.46 Cr 1418.2 6,612 543 -14.3% -4.0% 8.2% 206.4
Dr Reddys Laborator…
Mar 2026 		₹110,089.41 Cr 1319.0 7,996 221 -12.5% -11.5% 2.8% 497.7
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores